To include your compound in the COVID-19 Resource Center, submit it here.

Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers